The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA) Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a $550K matchingfund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This additional funding will support adding hematocrit measurement to a future generation blood volume analyzer. The upgrade eliminate ...

Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market Penetration Recent sales wins include: "Our unwavering focus on expanding market presence continues to yield strong results. The strategic investments we've made in our sales and marketing efforts are clearly bearing fruit," stated Michael Feldschuh, CEO and President of Daxor. "This growth underscores the increasing recognition of our blood volume analysis technology as a critical tool in improving patient outcomes." Daxor Corporation ...

Oak Ridge, TN, June 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22nd, 2024 at the Rosen Shingle Creek Resort in Orlando, Florida. The AAHFN is a specialty organization dedicated to advancing nursing education, clinical practice, and research to improve heart failure patient outcomes. Register for the event HER ...

Core Insights - Daxor Corporation is a leader in blood volume measurement technology, showcasing its innovative BVA technology at the AAHFN Annual Meeting, emphasizing its potential to improve heart failure management and overall cardiovascular care [1][2] - The BVA-100® is the only FDA-cleared diagnostic blood test for accurate blood volume status and composition, with over 65,000 tests performed, significantly reducing mortality and readmissions in heart failure and critical care [1] - Daxor is engaged in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [1] Event Participation - Daxor Corporation will exhibit at the AAHFN 20th Annual Meeting from June 20-22, 2024, in Orlando, Florida, aimed at advancing nursing education and improving heart failure patient outcomes [2]

Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrated a lack of ...

The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring'24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from acro ...

450-Bed Hospital Purchases BVA-100™ Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor's BVA-100™ at a 450-bed teaching hospital in the greater Chicago area. "Hospitals are utilizing our BVA diagnostic to save money by reducing length of stay while improving Hospital Readmissions Reduction Program (HRRP) quality metrics such as 30 ...

Thank you, Natalie (ph), and good afternoon, everyone, and welcome to the Daxor Annual Shareholder Call. I would like to turn the floor over to our Chief Financial Officer, Robert Michel for some highlights from our financial performance. Bob? Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Conference Call March 25, 2024 4:00 PM ET Company Participants Michael Feldschuh - CEO Robert Michel - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcom ...

Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will also host the call to review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are welcome to submit questions in advance via ema ...

Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023. Management reported a NAV of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022. The unaudited operati ...